Motea Lab

The research laboratory of Edward A. Motea, PhD, is studying the molecular basis of carcinogenesis and genomic instability induced by endogenous and exogenous genotoxic agents, translesion DNA synthesis, persistent R-loops (RNA:DNA hybrid structures), and aberrant DNA damage response and repair pathways. The goal is to utilize the mechanistic insights gained from these studies to rationally develop novel therapeutic agents and innovative strategies for personalized medicine.

Get Research Updates

To stay up-to-date on the medical research work at IU School of Medicine, follow the IU School of Medicine research blog, where investigators throughout the school’s academic departments statewide post updates about their work.

Blogs Hub

Focus on Drug Resistance and Aberrant Growth of Cancer Cells

A key barrier in developing precision medicine for cancers is lack of a comprehensive understanding at the molecular level of what promotes drug resistance and aberrant growth of cancer cells compared to the normal cells. For example, inhibition of a critical DNA repair factor, poly(ADP-ribose) polymerase-1 (PARP1), is a promising strategy for targeting cancers with defective DNA double-strand break (DSB) repair such as BRCA1 and BRCA2 mutation-associated breast cancers. Deficiencies in BRCA1 and BRCA2 genes can compromise homologous recombination (HR) to repair double-strand breaks created by the loss of PARP1 activity, conferring cell death by synthetic lethality.

However, the rarity of breast tumors with BRCA deficiency currently restricts the therapeutic utility of PARP inhibitor (PARPi) monotherapy and several potential molecular mechanisms of resistance for PARP1i in BRCA-deficient breast cancers have been reported. One striking paradox, though, is that approximately 24 percent of high-grade triple negative breast cancers (TNBC) without a BRCA mutation responded positively to PARP1i in Phase II clinical trials. These confounding observations clearly posit a search for suitable predictive biomarkers (i.e., markers for resistance and sensitivity), novel therapeutic targets and innovative strategies that can potentiate the DNA damaging effects of PARP1i beyond BRCA deficiencies.

Active Research

The Motea lab is investigating the mechanistic basis for synthetic lethality between loss of both PARP activity and specific transcription termination factors in BRCA-proficient cancers. Specifically, this lab team is trying to understand how cancer cells with aberrant alterations in these factors can induce formation of genotoxic R-loops (three-stranded nucleic acid structures that contain RNA:DNA hybrid and a displaced single-stranded DNA) and genomic instability at the molecular level using proteomics, genomics, bioinformatics, molecular biology, chemical biology, and pharmacological approaches.

Overall, understanding the mechanisms underlying R-loop-mediated genomic instability may provide key insights into (1) unannotated biological pathways; (2) the pathogenesis of many diseases and syndromes including cancer and neurological disorders; and (3) identification of novel targets and innovative strategies to leverage the formation, resolution, and/or processing of R-loops for precision medicine.

Current Research Funding

  • Investigation of novel PARP1RPRD1B complex in R-loop regulation and DNA repair
    CTSI Biomedical Research Grant PI: Edward A. Motea 11/19/2018-11/18/2019

    Goal: To elucidate the role of PARP1/RPRD1B in co-transcriptional R-loop-induced genomic instability.
    Role: Principal Investigator

  • RPRD1BKub5Hera an RNAPII determinant that controls PARPi and IR sensitivity
    NIH/NCI, 1 R01 CA201489-02, Role: Co-Investigator (PI: Boothman, DA) 07/01/2016-06/30/2021

    This grant focuses on the lab’s discovery that Kub5/Hera (K-H) regulates RNAPII at specific genetic promoters that include CDK1 in a subset of BRCA-proficient cancers. Loss of K-H expression compromises homologous recombination (HR) and hypersensitizes cells to PARP inhibitors. Aim 1 focuses on determining the structure/function of K-H regulation of the CTD domain of RNPII binding to specific promoter regions of CDK1. Aim 2 studies examine the therapeutic index of K-H-deficient breast cancers that are, in turn, hypersensitive to PARP inhibitors. Overlap: None.

Recent Publications

A full list of publications from the Motea Lab is available on PubMed.

Research Team

The Motea lab welcomes creative collaborations. There are available openings for bright and highly motivated individuals for graduate and postdoctoral positions in the lab. Interested individuals can submit inquiries by email to

Edward A. Motea, PhD

Assistant Professor of Biochemistry & Molecular Biology